1127237-80-2

Upstream product

• 1127237-77-7 5-[13-cyclohexyl-3-methoxy-10-[[[(cyclobutyl)sulfonyl]amino]carbonyl]-7H-indolo[2,1-a][2]benzazepin-6-yl]-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester 

Downstream Products

• 1127237-91-5 N-(cyclobutylsulfonyl)-13-cyclohexyl-3-methoxy-6-[4-[[(2S)-2-(methoxymethyl)-4-morpholinyl]carbonyl]-1-methyl-1H-pyrazol-5-yl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide 
• 1127237-81-3 N-(cyclobutylsulfonyl)-13-cyclohexyl-3-methoxy-6-[1-methyl-4-[(3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl]-1H-pyrazol-5-yl]-7H-indolo[2,1-a][2]benzazepine-10-carboxamide 
• 1127237-87-9 N-(cyclobutylsulfonyl)-13-cyclohexyl-6-[4-(3,7-dioxa-9-azabicyclo[3.3.1]non-9-ylcarbonyl)-1-methyl-1H-pyrazol-5-yl]-3-methoxy-7H-indolo[2,1-a][2]benzazepine-10-carboxamide 

Relevant academic research and scientific papers

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The invention encompasses selected compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.